What are the pros of tirzepatide for weight loss?

Does tirzepatide actually produce better results than other options?

The short answer is yes, in direct comparison. The SURMOUNT-5 trial (published in the New England Journal of Medicine in 2025) ran tirzepatide against semaglutide 2.4 mg in 751 adults with obesity over 72 weeks. Tirzepatide produced greater average weight loss. That matters because, until recently, semaglutide 2.4 mg (Wegovy) was considered the benchmark injectable for weight management.

The mechanism is the reason. Tirzepatide binds to receptors for two gut hormones (GIP and GLP-1) rather than one. Both slow gastric emptying and reduce appetite signalling; together, their effect on caloric intake and body weight appears additive. You can read more about how the medicine works on the tirzepatide overview page.

In SURMOUNT-1 specifically, adults without diabetes taking the 15 mg maintenance dose saw average body-weight reductions around 20–21% over 72 weeks, figures that NICE cited when recommending tirzepatide in its technology appraisal TA1026. Those are trial averages, not guarantees; individual responses vary, and a prescriber's job is partly to help you set realistic expectations before you start.

Which patients tend to benefit most, and what does eligibility actually look like?

Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for certain ethnic backgrounds under UK clinical guidance. BMI alone does not determine approval, a prescriber reviews the whole picture, including other medicines you take, your medical history and any contraindications listed in the Mounjaro SmPC on the eMC.

For people who meet private eligibility criteria but face long NHS waiting lists or do not yet meet the phased NHS thresholds, a clinically regulated private route exists. The Mounjaro treatment page sets out what that involves in practice. On the NHS side, NICE TA1026 recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with the caveat that treatment is reviewed if less than 5% weight loss occurs after six months at the highest tolerated dose.

It is also worth noting what tirzepatide is not suited to. Pregnancy, breastfeeding and trying to conceive are all contraindications; under-18s fall outside the licensed indication. Anyone with a history of medullary thyroid carcinoma or MEN2 needs to discuss that with a prescriber before considering treatment. A question about suitability is one our prescribers hear most weeks, it is a reasonable one to bring.

How does the tolerability profile stack up as an advantage?

One of the practical pros of tirzepatide is that the side-effect profile, while real, is well-characterised and mostly manageable. The most common effects are gastrointestinal: nausea, constipation, diarrhoea, indigestion and occasional burping. They tend to be most noticeable in the first few days after starting or after a dose increase, then settle. The gradual titration schedule (beginning at 2.5 mg and stepping up roughly every four weeks) exists specifically to let the body adjust before moving to higher therapeutic doses.

The NHS tirzepatide information page lists the full side-effect profile alongside guidance on which symptoms warrant prompt medical attention. Pancreatitis is rare but serious; severe, persistent stomach pain that radiates to the back, with or without vomiting, needs urgent assessment. That is a standard caution across the GLP-1 class, underlined by MHRA safety communications. If you want a fuller look at the trade-offs before deciding, our pros and cons of Mounjaro page runs through both sides in detail, and you can also explore the specific advantages the medicine offers if you want to focus on the positive case first.

For women using oral contraceptives, there is one specific consideration: absorption of the pill may be reduced during the first four weeks of treatment and for four weeks after each dose increase, so an additional non-oral method is advisable during those windows. It is a practical point worth raising at consultation.

Does cost affect how the pros weigh up in practice?

Tirzepatide is available privately, and the cost is a real factor in any honest assessment of the advantages. Since Eli Lilly adjusted UK list pricing in September 2025, private market prices have ranged roughly £149–£375 per month depending on dose and provider, and our tirzepatide dosing and licensing information explains how dose levels relate to what you might expect to pay at each stage. The Mounjaro pricing page covers the cost context in full, including what any legitimate price should include, clinical assessment, the prescription itself, and ongoing clinical oversight. A figure that bundles none of those is worth scrutinising.

The broader point: for a Prescription-Only Medicine, the value of supervision is inseparable from the value of the medicine. A prescriber who re-reviews your case before each repeat, checks your weight and adjusts your dose appropriately, is part of what makes the treatment work. That is not a marketing point; it is what the clinical evidence is built on. Check whether the service you are considering offers that before treating price as the deciding factor. If you are ready to explore your options, you can check your eligibility with our prescribers at no cost.